Thymidylate synthase expression, p53, bcl-2, Ki-67 and p27 in colorectal cancer: Relationships with tumor recurrence and survival

Tumor Biology

Volumn 25, Issue 5-6, 2004, Pages 258-263

  Rosati, Gerardo ^a,c   Chiacchio, Rosistella ^a   Reggiardo, Giorgio ^b   De Sanctis, Domenico ^a   Manzione, Luigi ^a  

^a SAN CARLO HOSPITAL   (Italy)

^b Medi Service   (Italy)

^c NONE   (Italy)

Author keywords

bcl 2; Colorectal cancer; Ki 67; p27; p53; Thymidylate synthase

Indexed keywords

FLUOROURACIL; KI 67 ANTIGEN; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BIOACCUMULATION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; FEMALE; FOLLOW UP; FREQUENCY ANALYSIS; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TUMOR RECURRENCE;

EID: 11444255222     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000081389     Document Type: Article

References (22)

1. NIH Consensus Conference: Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990;264:1444-1449.
2. Mamounas E, Wieand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B vs. Dukes' C colon cancer: Results from four NSABP adjuvant studies (C-01, C-02, C-03, C-04). J Clin Oncol 1999;17:1349-1355.
3. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999;17:1356-1363.
4. Midgley R: Systemic adjuvant therapy of colon cancer; in Bleiberg H, Kemeny N, Rougier P, Wilke H (eds): Colorectal Cancer: A Clinical Guide to Therapy. London, Martin Dunitz, 2002, pp 127-134.
5. McLeod HL, Murray GI: Tumor markers of prognosis in colorectal cancer. Br J Cancer 1999;79:191-203.
6. American Society of Clinical Oncology: Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-2877.
7. Hamilton SR, Aaltonen LA: Pathology and genetics of tumours of the digestive system; in World Health Organization Classification of Tumours. Lyon, IARC, 2000.
8. Fleming ID, Cooper JS, Henson DE: AJCC Cancer Staging Manual, ed 5. Philadelphia, Lippincott-Raven, 1997.
9. Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B: Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 1999;104:263-269.
10. Marchetti A, Buttitta F, Merlo G, Diella F, Pellegrini S, Pepe S, Macchiarini P, Chella A, Angeletti CA, Callahan R: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993;53:2846-2851.
11. Tenjo T, Toyoda M, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Ohtani M, Nohara T, Kawasaki H, Tanigawa N: Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000;58:45-51.
12. Allegra CJ, Parr AL, Wold LE, Mahoney MR, Sargent DJ, Johnston P, Klein P, Behan K, O'Connell MJ, Levitt R, Kugler JW, Tirona MT, Goldberg RM: Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer. J Clin Oncol 2002;20:1735-1743.
13. Cascinu S, Ligi M, Graziano F, Del Ferro E, Valentini M, Grianti C, Bartolucci M, Catalano G: S-phase fraction can predict event free survival in patients with pT2-T3N0M0 colorectal carcinoma: Implications for adjuvant chemotherapy. Cancer 1998;83:1081-1085.
14. Edler D, Glimelius B, Hallstrom M, Jacobsen A, Johnston PG, Magnusson I, Ragnhammar P, Blomgren H: Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728.
15. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
16. Petersen S, Thames HD, Nieder C, Petersen C, Baumann M: The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 2001;44:322-333.
17. Palmqvist R, Sellberg P, Oberg A, Tavelin B, Rutegard JN, Stenling R: Low tumor cell proliferation at the invasive margin is associated with a poor prognosis in Dukes' stage B colorectal cancers. Br J Cancer 1999;79:577-581.
18. Chen YT, Henk MJ, Carney KJ, Wong WD, Rothenberger DA, Zheng T, Feygin M, Madoff RD: Prognostic significance of tumor markers in colorectal cancer patients: DNA index, S-phase fraction, p53 expression, and Ki-67 index. J Gastrointest Surg 1997;1:266-273.
19. Jansson A, Sun XF: Ki-67 expression in relation to clinicopathological variables and prognosis in colorectal adenocarcinomas. APMIS 1997;105:730-734.
20. Graziano F, Cascinu S: Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: How much evidence is enough? Ann Oncol 2003;14:1026-1038.
21. Watanabe T, Chung DC: Molecular prognostic markers and colorectal cancer: The search goes on. Gastroenterology 1998;114:1330-1332.
22. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, Papadimitriou C, Georgoulias V, Gatter KC, Harris AL, Koukourakis MI: Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999;86:1421-1430.